Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$5.1B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will look for improvements or surprises compared to previous quarters.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for Celcuity's valuation and future prospects.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1-2026, Celcuity reported an EPS of -$0.86, beating estimates by 19.63%, which led to an 8.23% increase in stock price the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall financial performance.

Management Promises & Guidance

Management committed to advancing clinical trials for their lead product candidates.
They indicated a focus on improving operational efficiencies.
Management expressed optimism about future partnerships and collaborations.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Celcuity's earnings report, given the company's recent EPS beats. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Celcuity continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could see a significant boost in stock price.

Bear Case

Conversely, if the company fails to meet expectations or provides vague guidance, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will be provided on clinical trial progress?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can greatly influence the company's future prospects.

Will management provide any guidance on revenue expectations for the upcoming quarters?

Clear revenue guidance is essential for understanding the company's growth trajectory and can significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent clinical trial advancements, which could lead to better-than-expected results.

Supporting Evidence

Celcuity has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting traders expect significant news.

Recent insider activity has been absent, indicating no major sell-off or lack of confidence from management.

Key Risk

If clinical trial updates indicate stronger efficacy than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for growth against the uncertainty of revenue and clinical trial outcomes.

Bull Confirmed If

A positive update on clinical trial results combined with a revenue guidance that exceeds expectations would confirm the bull case.

Bear Confirmed If

Failure to provide any revenue guidance or negative news regarding clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations and raises guidance, history suggests a potential stock increase of around 3.4% on the day.

In-Line / Cautious

If results are in line with previous quarters but lack clear guidance, the stock may see a muted reaction as investors digest the information.

Miss

Should the company miss expectations, history suggests a potential decline of about 2.4% on the day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any new data.
2Any commentary on partnerships or collaborations that could enhance growth.
3Insights into operational efficiencies that may impact future profitability.
4Management's perspective on market conditions and competitive landscape.
5Updates on regulatory approvals or hurdles that could affect product timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will look for improvements or surprises compared to previous quarters.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for Celcuity's valuation and future prospects.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

Management Promises & Guidance

Management committed to advancing clinical trials for their lead product candidates.
They indicated a focus on improving operational efficiencies.
Management expressed optimism about future partnerships and collaborations.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Celcuity's earnings report, given the company's recent EPS beats. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If Celcuity continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could see a significant boost in stock price.

Bear Case

Conversely, if the company fails to meet expectations or provides vague guidance, it could lead to a decline in investor confidence and stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates will be provided on clinical trial progress?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can greatly influence the company's future prospects.

Will management provide any guidance on revenue expectations for the upcoming quarters?

Clear revenue guidance is essential for understanding the company's growth trajectory and can significantly impact investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of recent clinical trial advancements, which could lead to better-than-expected results.

Supporting Evidence

Celcuity has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

The options market is pricing a larger move than historical averages, suggesting traders expect significant news.

Recent insider activity has been absent, indicating no major sell-off or lack of confidence from management.

Key Risk

If clinical trial updates indicate stronger efficacy than expected, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for growth against the uncertainty of revenue and clinical trial outcomes.

Bull Confirmed If

A positive update on clinical trial results combined with a revenue guidance that exceeds expectations would confirm the bull case.

Bear Confirmed If

Failure to provide any revenue guidance or negative news regarding clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations and raises guidance, history suggests a potential stock increase of around 3.4% on the day.

In-Line / Cautious

If results are in line with previous quarters but lack clear guidance, the stock may see a muted reaction as investors digest the information.

Miss

Should the company miss expectations, history suggests a potential decline of about 2.4% on the day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of ongoing clinical trials and any new data.
2Any commentary on partnerships or collaborations that could enhance growth.
3Insights into operational efficiencies that may impact future profitability.
4Management's perspective on market conditions and competitive landscape.
5Updates on regulatory approvals or hurdles that could affect product timelines.